Global /United States /Healthcare /Drug Manufacturers - General /ACUT

AccuStem Sciences, Inc.

ACUT

• OTCMKTS: ACUT • Delayed

0.2800USD 0%

As of 13 June 2026, AccuStem Sciences, Inc. has a market cap of $4.5M USD, ranking #44856 globally and #5712 in the United States. It ranks #3973 in the Healthcare sector, and #1276 in the Drug Manufacturers - General industry.

Global Rank

44856

Country Rank

5712

Sector Rank

3973

Industry Rank

1276

Key Stats

Market Cap

$4.5MUSD

Enterprise Value

$4.51MUSD

EBITDA (TTM)

-$1.76MUSD

Net Income (TTM)

-$1.76MUSD

PB Ratio

-1.3

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Wendy Blosser open_in_new

Employees

Founded

2013

Website

accustem.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-20%	-42%	-55%	-79%	-66%	-33%	-74%	-84%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	ACUT Accustem Sciences Inc ISIN: US00444A1016 Shares Out.: Shares Outstanding: 16.072M¹ Shares Float: 9.772M² TV: TradingView: OTC: ACUT SA: Stock Analysis: OTC: ACUT YF: Yahoo Finance: ACUT GF: Google Finance: OTCMKTS: ACUT BA: Barron's: ACUT MS: Morningstar: PINX: ACUT	0.2800 USD	TV: TradingView: OTC: ACUT SA: Stock Analysis: OTC: ACUT YF: Yahoo Finance: ACUT GF: Google Finance: OTCMKTS: ACUT BA: Barron's: ACUT MS: Morningstar: PINX: ACUT

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AccuStem Sciences, Inc.

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company has a partnership with EmeritusDX for the development of non-invasive blood testing technologies. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 17M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 12M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 8M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 6M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 3M%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 3M%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 7M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 6M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 6M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 4M%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 2M%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 2M%	14.6	United Kingdom

chevron_leftBack